Navigation Links
Soligenix Announces Preliminary Results of its Phase 2 Clinical Trial of orBec® in the Prevention of Acute GVHD
Date:10/25/2010

ducted primarily at the Fred Hutchinson Cancer Research Center in Seattle, WA and was supported, in large part, by a National Institutes of Health (NIH) grant.  The impetus for this NIH-funded prevention study came from two double-blind, randomized, placebo-controlled trials showing that orBec® was effective and safe as a treatment for acute gastrointestinal (GI) GVHD.  

Paul J. Martin, MD, Principal Investigator for the Phase 2 study and a Member, Fred Hutchinson Cancer Research Center stated, "Trials with orBec® have shown a consistent and positive clinical response in the treatment of acute GI GVHD.  We therefore designed a trial to determine whether orBec® could be used to prevent GVHD. Preliminary analysis indicates that administration of orBec®  starting before transplantation did not provide a statistically significant clinical advantage in preventing acute GVHD in this study, possibly because of confounding factors associated with the chemotherapy or radiation.  Preventive administration of orBec® to reduce the incidence or severity of GVHD warrants further investigation, for example, by starting orBec® dosing after transplantation, closer to the initial inflammatory insult of acute GVHD.  We are continuing to analyze the data in order to gain a better understanding of potential preventive treatment effects in this patient population and to determine the best approach for subsequent study."   

Dr. Martin continued, "In my mind, the results from this prevention study have no clinical implication regarding the likelihood of success in the ongoing Phase 3 study of orBec® for the treatment of acute GI GVHD."

"This Phase 2 clinical trial was truly proof-of-concept and the first of its kind. It was an aggressive approach to determining if a topically-a
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
9. Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... 2014 Adaptive Biotechnologies, a clinical stage diagnostics ... the adaptive immune system, is pleased to announce the ... Officer (CCO). The addition of Brain to the Company,s ... leading global healthcare companies, including Dean Schorno ... Genomic Health and Sean Nolan (CTO) from ...
(Date:9/16/2014)... , Sept. 16, 2014  Advanced Medical ... stage development company engaged primarily in the ... for diagnostic and therapeutic applications, today announced ... related to its brachytherapy products.  AMIC,s rights ... its license from Battelle, under which AMIC ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... IRVINE, Calif., June 12 Masimo (Nasdaq: ... Motion and Low-Perfusion pulse oximetry, announced today that three ... of Masimo PVI as a noninvasive and continuous measure ... week at the European Society of Anaesthesiology (ESA) Annual ...
... Safety and Biologic Activity Data Reviewed in End of Phase ... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a ... treatment of cardiovascular and metabolic disease, announced today that an ... VIA-2291 (atreleuton), was recently held with the U.S. Food and ...
Cached Medicine Technology:New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 2VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 3VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 4VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease 5
(Date:9/16/2014)... September 16, 2014 Advanced Fertility Center ... named by Houstonia Magazine as one of the Top ... Houstonia Magazine - a metropolitan magazine serving the Houston ... and recognize them for their outstanding services. This accomplishment ... edition of Houstonia Magazine — a special publication listing ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a ... $10,000 in a 0% interest free, 2nd down payment assistance ... federal programs, are listed on their private website. The $10,000 ... or move out of the property. The down payment assistance ... no monthly payments paid by the Borrower. The money is ...
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT ... for its high morale and collaborative culture ... Firms to Work For 2014.” Consulting magazine publishes ... 10,000 consultants participating across all major industries, representing more ... conducted, and firms were ranked in six categories - ...
(Date:9/16/2014)... 14, 2014 A new clinical trial ... and drug-eluting balloons (DEB) in treating in-stent ... EES provided superior late angiographic results and ... were reported today at the 26th annual ... by the Cardiovascular Research Foundation (CRF), TCT ...
(Date:9/16/2014)... Ensuring that corn absorbs the right balance of nitrogen, ... a Purdue and Kansas State University study finds. , ... from the U.S. and other regions showed that high ... plants took up key nutrients at specific ratios - ... nitrogen and potassium at a ratio of 1-to-1. These ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3
... Optical technology is as accurate as colorectal tissue examination, ... Optical technology could help physicians detect small colorectal polyps ... , In the report, published online Nov. 10 in ... that the technique could replace histopathology, which requires more ...
... cancer has eliminated tumours in 50% of mice in a new ... the animals, the drug also stopped lung cancer tumours from growing ... Imperial College London, are now planning to take the drug into ... with an inoperable form of lung cancer. One in five ...
... 10 Reportlinker.com announces that a new ... catalogue. , Central Nervous System ... http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , Life ... Sleep Disorders contains detailed information on the ...
... Hospital Dallas is the first hospital in Dallas and one ... Cycle III Chest Pain Center by the Society of Chest ... , "This honor means that Texas Health Presbyterian Dallas ranks ... collaborative treatment of heart attacks," said cardiologist Dr. John Harper, ...
... estimates 2,266 U.S. military veterans under the age of 65 died ... access to care. That figure is more than 14 times the ... 2008, and more than twice as many as have died (911 ... The researchers, who released their analysis today, pointedly say the health ...
... But researchers not exactly sure how pathogens raise risk of ... to several common pathogens may increase the risk of having ... Mitchell Elkind, an associate professor of neurology at Columbia University ... that the pathogens Chlamydia pneumoniae , Helicobacter pylori ...
Cached Medicine News:Health News:New Polyp Detection Method Could Be Cost-Saver 2Health News:Drug shrinks lung cancer tumors in mice 2Health News:Drug shrinks lung cancer tumors in mice 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2Health News:Common Infections May Contribute to Strokes 2Health News:Common Infections May Contribute to Strokes 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Micro emulsifying needles, 18G....
Micro 2000, micro scissors micro 2000 supercut....
Yasargil clip applying forceps Mini. Stainless steel jaw....
Medicine Products: